|Bid||1,426.20 x 0|
|Ask||1,426.60 x 0|
|Day's Range||1,410.60 - 1,434.20|
|52 Week Range||1,190.80 - 1,528.80|
|Beta (5Y Monthly)||0.38|
|PE Ratio (TTM)||16.46|
|Earnings Date||Oct 27, 2021|
|Forward Dividend & Yield||0.80 (5.64%)|
|Ex-Dividend Date||Aug 19, 2021|
|1y Target Est||N/A|
Dr. Cedric Dark, Assistant Professor at Baylor College of Medicine & Board Member with Doctors for America, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
23andMe Co-Founder & CEO Anne Wojcicki joins 'Influencers with Andy Serwer' to discuss the future of personal genomics.
(Bloomberg) -- Activist hedge fund Bluebell Capital Partners disclosed a stake in GlaxoSmithKline Plc, ratcheting up pressure on Chief Executive Officer Emma Walmsley after Elliott Investment Management targeted her leadership of the U.K. drugmaker.Most Read from BloombergThe Global Housing Market Is Broken, and It’s Dividing Entire CountriesIstanbul Turns Taps on Old Fountains, Joining Global Push for Free DrinksIn Paris, the Wrapped Arc de Triomphe Is a Polarizing PackageHow the Child Care Cri